Document Detail

RUNX3 protein is overexpressed in human epithelial ovarian cancer.
MedLine Citation:
PMID:  18937968     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: RUNX family genes, including RUNX3, are developmental regulators that are important in human cancers. The purpose of this study was to evaluate expression and oncogenic potential of RUNX3 in ovarian carcinoma. METHODS: Immunohistochemical staining was performed on 60 malignant, 14 borderline, and 5 normal ovarian specimens. Correlation between RUNX3 expression with tumor histology was performed. RUNX3 expression was evaluated by quantitative real-time polymerase chain reaction (QRT-PCR) in microdissected normal and malignant epithelial ovarian tissues. Cell proliferation and viability studies were performed on cells expressing RUNX3 by lentiviral infection and cells with silenced RUNX3 expression by siRNA. RESULTS: RUNX3 expression by immunohistochemistry was higher in serous ovarian carcinomas versus normal ovarian epithelium (P<0.001). Immunofluorescent staining confirmed upregulation of cytoplasmic RUNX3 in ovarian cancer cell lines and tissues. QRT-PCR showed higher RUNX3 mRNA expression in microdissected borderline and malignant ovarian tumor tissues compared with the normal ovarian surface epithelial cells (HOSE) (P=0.006 and P=0.023). Forced RUNX3 expression by lentiviral gene delivery in ovarian cancer cells, SKOV3, that initially showed undetectable RUNX3 expression, resulted in increased cell viability (P=0.043). Silencing RUNX3 expression by siRNA transfection into ovarian cancer cells, OVCAR429, initially expressing high levels of endogenous RUNX3 resulted in a decrease in proliferation (P=0.021). CONCLUSION: These results suggest that RUNX3 has a role in cell proliferation and viability in ovarian cancer.
Nicole S Nevadunsky; John S Barbieri; Joseph Kwong; Melissa A Merritt; William R Welch; Ross S Berkowitz; Samuel C Mok
Related Documents :
11925128 - Serum, pleural effusion, and ascites ca-125 levels in ovarian cancer and nonovarian ben...
8146528 - Factors effecting the measurement of tumor-associated muc1 mucins in serum.
3799638 - Familial ovarian carcinoma. clinical nuances.
10397458 - C-erbb-2 oncoprotein assay in ovarian carcinoma and its clinical correlation with progn...
10785588 - Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-ap...
15650248 - Steroids as procarcinogenic agents.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2008-10-19
Journal Detail:
Title:  Gynecologic oncology     Volume:  112     ISSN:  1095-6859     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-19     Completed Date:  2009-01-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  325-30     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Laboratory of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Growth Processes / physiology
Cell Line
Core Binding Factor Alpha 3 Subunit / biosynthesis*,  genetics
Cytoplasm / metabolism
Gene Expression Regulation, Neoplastic
Gene Silencing
Ovarian Neoplasms / genetics,  metabolism*,  pathology
Ovary / metabolism,  physiology
RNA, Messenger / biosynthesis,  genetics
RNA, Small Interfering / genetics
Grant Support
Reg. No./Substance:
0/Core Binding Factor Alpha 3 Subunit; 0/RNA, Messenger; 0/RNA, Small Interfering; 0/Runx3 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Next Document:  Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis.